Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mirna Therapeutics has received notice of allowance from the USPTO related to the therapeutic application of let-7 in the regulation of oncogenes.
Subscribe to our email newsletter
Let-7 was the first miRNA that was demonstrated to function as a tumor suppressor via its ability to regulate oncogene expression, Mirna Therapeutics said.
Mirna Therapeutics said that the claims derive from a patent application that was submitted by Yale University and exclusively licensed to Mirna related to the work of Frank Slack, professor of Molecular, Cellular & Developmental Biology at Yale University in New Haven, CT.
During an extended collaboration, scientists at Mirna and Yale have shown that let-7 regulates multiple cancer-related genes and pathways, influences the sensitivity of cancer cells to radiation and chemotherapy, and affects tumor development.
Using transgenic and xenograft mouse models of cancer, the two labs have demonstrated that therapeutic candidates featuring the let-7 sequence inhibit tumor development and growth.
Mirna Therapeutics president and CEO Paul Lammers said that they were excited about the potential of let-7 based therapies being used either alone or in combination with traditional and/or targeted therapies to enhance cancer patient care.